Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064 · View on ClinicalTrials.gov ↗
Study Summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Conditions Studied
Interventions
- DRUG EYP-1901
- DRUG Aflibercept (2.0 mg)
Study Locations (20)
California
- California Retina Consultants — Bakersfield
- Retina Vitreous Associates Medical Group — Beverly Hills
- Macula and Retina Institute — Glendale
- Retina Consultants San Diego — Poway
- Retina Consultants of Southern California — Redlands
- Retinal Consultants Medical Group — Sacramento
- West Coast Retina Medical Group — San Francisco
- Bay Area Retina Associates — Walnut Creek
- American Institute of Research — Whittier
Colorado
- RSC Research, PLLC — Denver
- Eye Center of Northern Colorado, PC — Fort Collins
- Advanced Vision Institute — Longmont
Connecticut
- Connecticut Eye Consultants, P.C. — Danbury
- SightSera Clinical Research LLC — Greenwich
- Retina Group of New England, PC — Waterford
Florida
- Advanced Research, LLC — Deerfield Beach
- Florida Retina Consultants — Lakeland
- Florida Retina Institute — Orlando
Arizona
- Retinal Research Institute, LLC — Phoenix
Arkansas
- Retina Partners of Northwest Arkansas — Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06668064
The ClinicalTrials.gov registry entry for NCT06668064 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyePoint Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with wAMD appearing as the primary indexed condition, and to 2 interventions — of which EYP-1901 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06668064 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Colorado, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06668064 about?
NCT06668064 is a clinical study titled "A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56". This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
What is the current status of trial NCT06668064?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2024-10-22. Estimated completion is 2027-08.
What conditions does trial NCT06668064 study?
This clinical trial studies the following conditions: wAMD, Wet Age Related Macular Degeneration. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06668064?
The interventions under investigation include: EYP-1901 (DRUG), Aflibercept (2.0 mg) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06668064?
This trial is sponsored by EyePoint Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06668064 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.